Biovaxys Technology Corp Stock Price To Earnings To Growth
| BVAXF Stock | USD 0.04 0 10.86% |
Biovaxys Technology Corp fundamentals help investors to digest information that contributes to Biovaxys Technology's financial success or failures. It also enables traders to predict the movement of Biovaxys OTC Stock. The fundamental analysis module provides a way to measure Biovaxys Technology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biovaxys Technology otc stock.
Biovaxys |
Biovaxys Technology Corp OTC Stock Price To Earnings To Growth Analysis
Biovaxys Technology's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Based on the latest financial disclosure, Biovaxys Technology Corp has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The price to earnings to growth for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Money Managers Now
Money ManagersScreen money managers from public funds and ETFs managed around the world |
| All Next | Launch Module |
Biovaxys Fundamentals
| Return On Equity | -0.73 | |||
| Return On Asset | -0.38 | |||
| Current Valuation | 11.35 M | |||
| Shares Outstanding | 106.72 M | |||
| Shares Owned By Insiders | 18.94 % | |||
| Price To Earning | (4.32) X | |||
| Price To Book | 2.53 X | |||
| EBITDA | (6.44 M) | |||
| Net Income | (6.46 M) | |||
| Cash And Equivalents | 39.05 K | |||
| Current Ratio | 0.16 X | |||
| Book Value Per Share | 0.06 X | |||
| Cash Flow From Operations | (5.29 M) | |||
| Earnings Per Share | (0.05) X | |||
| Number Of Employees | 17 | |||
| Beta | -0.59 | |||
| Market Capitalization | 8.73 M | |||
| Total Asset | 8.5 M | |||
| Retained Earnings | (80 M) | |||
| Working Capital | 35 M | |||
| Current Asset | 37 M | |||
| Current Liabilities | 2 M | |||
| Z Score | -7.8 | |||
| Net Asset | 8.5 M |
About Biovaxys Technology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biovaxys Technology Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biovaxys Technology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biovaxys Technology Corp based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Biovaxys OTC Stock
Biovaxys Technology financial ratios help investors to determine whether Biovaxys OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biovaxys with respect to the benefits of owning Biovaxys Technology security.